Molecular diagnostics

The World Market for Molecular Diagnostics 12th Edition, Featuring Competitive Analysis of Advanced Cell Diagnostics, Berry Genomics, Biocartis, bioMerieux, CareDx, Danaher, Hologic, Illumina & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Science, Research, Pharmaceutical, Medical Supplies, General Health, Health, Infectious Diseases, Health Technology, Gen-Probe, Polymerase, NGS, Coagulation, Hepatitis, Fungal infection, Medicine, Infection, NAT, Molecular diagnostics, Geography, Urine, Roche, IVD, TB, Respiratory disease, Developed country, Gene, Human leukocyte antigen, Cancer, Prognosis, Single-nucleotide polymorphism, Risk, Polymerase chain reaction, HLA, Safety, COVID-19, Massive parallel sequencing, Immunoassay, Physician, HIV, BD (company), HPV, DSM-IV codes, PCR, AMR, Metabolism, Pharmacokinetics, Diagnosis, Blood, Growth, Vaccine

Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.

Key Points: 
  • Recent years saw molecular diagnostics emerge as the fastest growing segment within the global in vitro diagnostics (IVD) market.
  • This new report reveals that post-pandemic the market remains ripe with opportunity, notably in the areas of infectious diseases, cancer, and transplant diagnostics.
  • Molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare.
  • This report evaluates the present configuration of the molecular diagnostics market in cancer, providing insights into prominent products and geographical segmentation.

Point-of-Care Molecular Diagnostics Market Expected to Reach USD 10.12 Billion by 2030, Driven by Technological Advancements and Growing Geriatric Population - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 9, 2024
COVID-19, Telemedicine, Virtual Medicine, Other Health, Pharmaceutical, Practice Management, Oncology, Medical Devices, Infectious Diseases, Hospitals, Science, Biotechnology, AIDS, Other Science, Health, Medical Supplies, Ageing, NGS, Infection, Research, Molecular diagnostics, Prenatal testing, CRISPR, Prenatal development, Cancer, Point, USD, HIV, POC, PCR, Compound annual growth rate, Growth

Recent findings suggest an impending upsurge in the global Point-of-Care (POC) Molecular Diagnostics market, with forecasts estimating a valuation of USD 10.12 billion by the year 2030.

Key Points: 
  • Recent findings suggest an impending upsurge in the global Point-of-Care (POC) Molecular Diagnostics market, with forecasts estimating a valuation of USD 10.12 billion by the year 2030.
  • This relates to a Compound Annual Growth Rate (CAGR) of 2.5% over the period from 2024 to 2030.
  • The market analysis indicates a substantial need for POC molecular diagnostics, particularly for infections like COVID-19 and HIV, and to bolster ongoing monitoring in home healthcare settings.
  • The research addresses crucial data that underpin strategic decisions and forecasted growth, setting the stage for ongoing and future developments in the POC molecular diagnostics landscape.

Molecular HPV Testing: 6.6% Revenue Growth 2023-2028, reports Kalorama Information

Retrieved on: 
Thursday, January 11, 2024
Gen-Probe, World Health Organization, Medicine, Incidence, Molecular diagnostics, Roche, TB, Tuberculosis, Cancer, Workflow, Vaccination, Risk, Infection, Sale, PAP, Cervical cancer, Food, WHO, COVID-19, STI, FDA, HIV, BD (company), HERE, HPV, Treatment, News, Growth, Vaccine

ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition, a new report published by leading medical market research firm Kalorama Information. The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.

Key Points: 
  • ARLINGTON, Va., Jan. 11, 2024 /PRNewswire-PRWeb/ -- Human papillomavirus (HPV) testing is a key segment of the double-digit, multi-billion-dollar global molecular diagnostic testing market, according to The World Market for Molecular Diagnostics, 12th Edition , a new report published by leading medical market research firm Kalorama Information.
  • The report reveals that through 2028, molecular HPV testing will grow 6.6%—outpacing growth in several other notable molecular testing segments including HIV, STIs, and genetic/inherited diseases.
  • Today, molecular diagnostics has evolved into an essential instrument in clinical medicine, influencing various facets of healthcare, according to Kalorama Information.
  • Recently growth in molecular diagnostics methods has also been coming from cancer, TB, ISH/ FISH, and other areas.

BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

Retrieved on: 
Friday, January 5, 2024
Molecular diagnostics, Acquisition, MBA, Genomics, University, Holy Cross, ANSA, Diagnosis, Growth, Economics, Management

MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.

Key Points: 
  • MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024.
  • Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular Diagnostics Division following its acquisition of Asuragen, where Dr. McManus served as President and CEO.
  • "I am excited for Matt's return to Bio-Techne," said Kim Kelderman, Bio-Techne's Chief Operating Officer and in-coming Chief Executive Officer.
  • Matt is the ideal candidate to take the Diagnostics and Genomics Segment through its next phase of growth."

Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders

Retrieved on: 
Thursday, December 21, 2023
Doctor of Pharmacy, NGS, Medicine, Molecular diagnostics, Research, Hospital, Cell biology, Sophia Genetics, GENETICS, MPN, Artificial intelligence, Patient, Platform, Myeloproliferative neoplasm, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Dec. 21, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS.

Key Points: 
  • The implementation of the SOPHiA DDM™ Platform will help the Cellular Biology Department expedite its research and increase its ability to provide data-driven care to patients with MPN.
  • "The SOPHiA DDM™ Platform has been an essential tool to support us in streamlining our bioinformatics workflows, expediting our research, and making data-driven decisions for our patient population."
  • The SOPHiA DDM™ Platform is a NGS-based application that uses artificial intelligence (AI) to efficiently analyze and interpret raw NGS data for researchers.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on X , LinkedIn , Facebook , and Instagram .

BostonGene to Showcase AI-Driven Molecular Profiling Solutions at the Association for Molecular Pathology 2023 Annual Meeting

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, MSI, WES, TMB, American Securities, Salt Palace, Sequence, Epigenome-wide association study, Molecular diagnostics, Agilent Technologies, Journal, HRD, Chromosomal translocation, R, Molecular reference standards, AMP, Abstract (summary)

BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.

Key Points: 
  • BostonGene , a leading provider of AI-driven molecular and immune profiling solutions today announced that an abstract has been accepted as a poster presentation for the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, which will be held November 14 - 18, 2023, at the Salt Palace Convention Center in Salt Lake City, UT.
  • During the event, BostonGene will also deliver a presentation at the AMP Corporate Workshop day and exhibit at booth 1301.
  • Details of BostonGene’s presence at AMP are below:
    Speaker: Katerina Nuzhdina, R&D, Head of Bioinformatics Pipelines Clinical Integration Division, BostonGene
    Tumor molecular characterization is key for advancing precision oncology.
  • In collaboration with Agilent, BostonGene will present its method for detecting somatic variants from cancer samples, enabling large-scale data analyses.

QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER

Retrieved on: 
Monday, October 30, 2023
PDF, Plant, QGEN, Molecular diagnostics, NYSE, Tax, Public expenditure, EBITDA, GAAP, EPS, COVID-19, QIAGEN, Forecasting, Table, CER, Growth

Net sales results of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio.

Key Points: 
  • Net sales results of $470 million at constant exchange rates (CER) for Q3 2023 were above the outlook for at least $465 million CER, driven by 5% CER growth in the non-COVID-19 portfolio.
  • Overall sales results for Q3 2023 declined 5% (-6% CER) to $476 million from Q3 2022, a period marked by significant COVID-19 sales contributions.
  • Adjusted diluted earnings per share (EPS) were $0.50, and results of $0.50 CER were above the outlook for at least $0.48 CER.
  • These results include adjusted net sales, adjusted gross income, adjusted gross profit, adjusted operating income, adjusted operating expenses, adjusted operating income margin, adjusted net income, adjusted net income before taxes, adjusted diluted EPS, adjusted EBITDA, adjusted EPS, adjusted income taxes, adjusted tax rate, and free cash flow.

Molecular Diagnostics Segment Poised for Robust 7.1% CAGR, Reflecting the Growing Role of Pathology in Drug Development and Molecular Diagnostics Services - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health Technology, Health, Growth, Molecular diagnostics, Drug discovery, Policy, Prevalence, South African Unemployed Peoples' Movement, War, Real, Tourism, Pathology, Service

Although Declining for the First Time Since the Russia-Ukraine War, Global Oil Prices Still Remains Higher Than 2019 Levels Which In Turn Will Take Inflation Longer Than Expected to Fall: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024

Key Points: 
  • Although Declining for the First Time Since the Russia-Ukraine War, Global Oil Prices Still Remains Higher Than 2019 Levels Which In Turn Will Take Inflation Longer Than Expected to Fall: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2017 through 2024
    Slower Than Anticipated Decline Makes Inflation a Stickier Than Expected Problem to Solve in 2023: Global Inflation Rates (In %) for the Years 2019 through 2024
    Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Persistent Challenges & Slower Decline in Underlying Core Inflation: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
    Inflation Battling Policy Measures to Slowdown Post Pandemic Recovery in Unemployment Rates: Global Number of Unemployed People (In Million) for Years 2019 Through 2024
    Rising Prevalence of Chronic/Infectious Diseases Drives Demand for Pathology Instruments & Devices Powering Modern Diagnostics: Global Cost of Chronic Diseases (In US$ Trillion) for the Years 2023, 2025, 2027, 2029 and 2031
    Robust Growth of Molecular Diagnostics Services Expands the Opportunity Avenue for Pathology Instruments: Global Market for Molecular Diagnostics (In US$ Million) for Years 2023, 2025 and 2027
    From Microscope to Market, Pathology's Pivotal Role in Drug Evolution Cannot be Undermined: Global Market for Drug Discovery (In US$ Billion) for Years 2023, 2025, 2027, 2029 and 2031
    Growing Demand for Forensic Technologies & Services Translates Directly into Increased Sales of Pathology Instruments: Global Market for Forensic Technologies & Services (In US$ Million) for Years 2023, 2025, 2027 and 2029

Longhorn Vaccines and Diagnostics Announces Data Showing PrimeStore® Molecular Transport Medium Inactivates High Consequence Animal Viruses

Retrieved on: 
Thursday, October 12, 2023
Veterinary, Health, Food, Vaccine, Pithing, BioRxiv, Doctor of Philosophy, Livestock, Public, Accuracy and precision, Animal, ASF, Safety, Collection, Virus, African swine fever virus, Influenza B virus, Poultry, SARS-CoV-2, Virulent Newcastle disease, Molecular diagnostics, Human, HPAI, Zoonosis, Dicarboxylic acid, Animal husbandry, Longhorn, DVM

Zoonotic diseases are a significant threat to human and animal populations and global food production.

Key Points: 
  • Zoonotic diseases are a significant threat to human and animal populations and global food production.
  • This includes the SARS-CoV-2 global pandemic that has dramatically affected humans and domestic and wild animal species.
  • The study, titled “Inactivation of Highly Transmissible Livestock and Avian Viruses Including Influenza A and Newcastle Disease Virus for Molecular Diagnostics,” found:
    PS-MTM completely inactivates viruses representing highly contagious animal diseases in the presence of species-relevant sample matrices.
  • Add to that the biosafety and biosecurity risks of transporting high consequence disease samples and the typical need to keep samples cold.

Acutis Biosciences' CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Retrieved on: 
Thursday, September 7, 2023
Tissue, DNA, The New England Journal of Medicine, LDT, Qualitative research, Circulating tumor DNA, Therapy, NGS, 2005 in television, Liquid biopsy, CTA, Toxicology, Taiho Pharmaceutical, Biomarker, IHC, NEJM, CLIA, Patient, Medicine, Neoplasm, CDX, FDA, FGFR2, PCR, Cholangiocarcinoma, Medical imaging, Pharmaceutical industry, Medical device, Molecular diagnostics

Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.

Key Points: 
  • Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.
  • The study demonstrated the clinical value of circulating tumor DNA (ctDNA) in molecular profiling to assess patient's eligibility for targeted therapeutics.
  • With ctDNA blood samples you are guaranteed as low as 1% failure rate compared to tumor tissues" said Dr. Halim.
  • Acutis CEO Jibreel Sarij added, "Dr. Halim and his team are making significant impact to bring forward clinical research testing and genomic profiling to enable biopharma with deeper insights and transform precision medicine".